Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing 100730 China.
Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing 100730 China.
Vision Res. 2023 Sep;210:108273. doi: 10.1016/j.visres.2023.108273. Epub 2023 Jun 10.
The rapid evolution of two technologies has greatly transformed the basic, translational, and clinical research in the mammalian retina. One is the retinal organoid (RO) technology. Various induction methods have been created or adapted to generate species-specific, disease-specific, and experimental-targeted retinal organoids (ROs). The process of generating ROs can highly mimic the in vivo retinal development, and consequently, the ROs resemble the retina in many aspects including the molecular and cellular profiles. The other technology is the gene editing, represented by the classical CRISPR-Cas9 editing and its derivatives such as prime editing, homology independent targeted integration (HITI), base editing and others. The combination of ROs and gene editing has opened up countless possibilities in the study of retinal development, pathogenesis, and therapeutics. We review recent advances in the ROs, gene editing methodologies, delivery vectors, and related topics that are particularly relevant to retinal studies.
两种技术的快速发展极大地改变了哺乳动物视网膜的基础、转化和临床研究。一种是视网膜类器官(RO)技术。已经创建或改编了各种诱导方法来产生种特异性、疾病特异性和实验靶向的视网膜类器官(RO)。生成 RO 的过程可以高度模拟体内视网膜发育,因此,RO 在许多方面与视网膜相似,包括分子和细胞特征。另一种技术是基因编辑,以经典的 CRISPR-Cas9 编辑及其衍生物(如 Prime 编辑、同源独立靶向整合(HITI)、碱基编辑等)为代表。RO 与基因编辑的结合在视网膜发育、发病机制和治疗学的研究中开辟了无数的可能性。我们回顾了 RO、基因编辑方法、递送载体和与视网膜研究特别相关的相关主题的最新进展。